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Abstract 
Recent large-scale genetic studies have allowed for the first glimpse of the effects of common genetic variability in dementia with 
Lewy bodies (DLB), identifying risk variants with appreciable effect sizes. However, it is currently well established that a 
substantial portion of the genetic heritable component of complex traits is not captured by genome-wide significant SNPs. To 
overcome this issue, we have estimated the proportion of phenotypic variance explained by genetic variability (SNP heritability) 
in DLB using a method that is unbiased by allele frequency or linkage disequilibrium properties of the underlying variants. This 
shows that the heritability of DLB is nearly twice as high as previous estimates based on common variants only (31% vs 59.9%). 
We also determine the amount of phenotypic variance in DLB that can be explained by recent polygenic risk scores from either 
Parkinson’s disease (PD) or Alzheimer's disease (AD), and show that, despite being highly significant, they explain a low amount 
of variance. Additionally, to identify pleiotropic events that might improve our understanding of the disease, we performed genetic 
correlation analyses of DLB with over 200 diseases and biomedically relevant traits. Our data shows that DLB has a positive 
correlation with education phenotypes, which is opposite to what occurs in AD. Overall, our data suggests that novel genetic risk 
factors for DLB should be identified by larger GWAS and these are likely to be independent from known AD and PD risk variants. 
 
Keywords: dementia Lewy bodies, genetic variance, polygenic risk
Introduction 
Recent studies have highlighted the role of genetics in the common, but 
often underappreciated, form of dementia that is dementia with Lewy 
bodies (DLB). Associations with GBA, APOE and SNCA have all been 
reproducibly reported by independent groups (1–3), and a recent genome-
wide association study (GWAS) identified several risk and candidate 
variants associated with the disease (4). However, GWAS significant 
single nucleotide polymorphisms (SNPs) often explain only a small 
proportion of the total heritability estimated (usually from family-based 
studies) for a given trait, which results in the ‘missing heritability’ issue 
(5). One of the possible explanations for this issue is that all common 
SNPs, regardless of their association p-value, contribute to the 
heritability of complex traits (6–8). However, given that each individual 
associated marker explains only a small proportion of the genetic 
variation with little predictive power, methods have been developed to 
test disorder prediction by summarizing variation across many loci 
(regardless of association p-values) into quantitative scores. One such 
approach is the generation of polygenic risk scores (PRSs). PRSs have 
been successfully applied to Parkinson’s (PD) (9) and Alzheimer’s 
diseases (AD) (10) and their usefulness will continue to increase as 
discovery datasets are augmented.  
A separate, but related, concept is that of genetic correlation of traits. 
Here, what is estimated is the genetic covariance between traits that is 
tagged by common genome-wide SNPs (11). This allows us to identify 
pleiotropic effects between traits that might be unrelated by any other 
measurement. We have performed a preliminary study of genetic 
correlation between DLB and both PD and AD (12), however performing 
similar analyses with other (even apparently unrelated) traits might 
provide novel insights for the underlying pathobiology of disease and 
perhaps for treatments across diseases. 
The phenotypic variance of most complex human traits combines the 
genetic with the environmental variance (13). While the effects of the 
environment are difficult to ascertain given their complexity and lack of 
adequate measurements, we are able to determine the genetic variance 
more accurately. Classically, genetic variance has been partitioned into 
sources of variation due to additive, dominance and epistatic effects. 
Additive genetic variance (h2SNP) relates to an allele’s independent effect 
on a phenotype; dominance variance (δ2SNP) refers to the effect on a 
phenotype caused by interactions between alternative alleles at a specific 
locus; epistatic variance refers to the interaction between different alleles 
in different loci. Most available cohorts for studies of human biology and 
disease are still underpowered to identify epistatic events, however, 
additive and dominance variance can be estimated from standard 
genome-wide genotyping data (14).  
Here, using data from the first GWAS in DLB that included haplotype 
reference consortium (HRC)-imputed genotypes (15), we have estimated 
the total heritability of this disease. We used a method (GCTA-LDMS) 
that is unbiased regardless of the minor allele frequency (MAF) and 
linkage disequilibrium (LD) properties of variants and thus greatly 
improves on previous estimates (16). Since it has been suggested that 
heritability estimates may be inflated by non-additive variation (17), we 
have also estimated the dominance genetic variation in DLB. 
Additionally, to measure the proportion of variance explained by PRSs 
from PD and AD in a large DLB cohort, we measured the ability of PRS 
to discriminate case from control subjects. Lastly, to attempt to derive 
novel biological insights from unrelated traits, we have performed 
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pairwise genetic correlation analysis of DLB with 235 phenotypes, 
including cognitive, anthropometric and education traits. 
Results 
Quantifying the genetic heritability of DLB 
We applied the GREML-LDMS approach to estimate the proportion of 
phenotypic variance explained by the HRC-imputed variants for DLB. 
Results from this approach showed that imputed variants with R2 greater 
than or equal to 0.3 and frequency above 0.1% explained 59.9% (s.e.= 
2.1%; p=6.8x10-6) of phenotypic variance for DLB. Lower frequency 
variants explained a large proportion of the phenotypic variance in DLB. 
This pattern was maintained for the higher quality imputed variants as 
well (Figure 1, Supplementary Table 1). 
To determine if non-additive variance in DLB would explain a subset of 
the total disease heritability, we calculated the disease dominance 
variance as implemented in the tool GCTA-GREMLd. This method uses 
genome-wide data to estimate the additive and dominance genetic 
relationship matrices (GRMs) and fits both GRMs in a mixed linear 
model to estimate h2SNP and δ2SNP simultaneously. Our results suggest that 
DLB does not show significant dominance variance with an overall 
estimate δ2SNP=-0.05 (s.e. = 0.02). 
Polygenic Prediction of Case-Control Status 
We applied the PRSs derived from AD and PD data to determine if these 
would discriminate between DLB and controls. The AD score explained 
1.33% of the variance (Nagelkerke’s pseudo-R2) and was highly 
significant (p = 5.8x10-31). Performing the same analysis while excluding 
the APOE locus brought the estimate down to 0.14%, while reaching only 
nominal significance. Using the PD polygenic risk score, we obtained an 
estimate of 0.37% of the variance in DLB being explained by that score, 
a result that was also significant (p=6.4x10-10). Interestingly, removing 
the GBA locus resulted in only a small reduction in the variance explained 
by the PD PRS (0.36%; p=1.23x10-9) at the best p-value threshold. 
The bar plots of DLB variance explained by the AD and PD polygenic 
risk scores are presented in Figure 2. As expected given these results, 
DLB cases had on average higher polygenic risk scores than control 
subjects for both PD and AD (Figure 3). 
Unbiased genetic correlation 
To test whether DLB has a shared genetic etiology with any of 235 other 
diseases or biomedical relevant traits, we used LD score regression as 
implemented in LDHub (http://ldsc.broadinstitute.org/ldhub/). This 
method estimates the degree to which genetic risk factors are shared 
between pairs of diseases or traits, although it should be noted that it does 
not inform regarding how this shared genetic etiology arises. We selected 
the correlations with a p-value <0.01 in DLB and tested these in AD and 
PD (Figure 4). 
 
Fig. 1. Estimate of the DLB variance explained by HRC-imputed 
variants by MAF and LD. Segmental LD score increases from the 1st to 
4th quartiles. Negative scores are not shown for simplicity but are present 
in Supplementary Table 1. The estimates of variance explained are from 
the GREML-LDMS analyses of fitting all the 24 genetic components 
simultaneously. 
Fig. 2. Proportion of variance of DLB case-control status explained by 
PRSs from AD (A), AD excluding the APOE locus (B), PD (C) and PD 
excluding the GBA locus (D). The bars represent PRSs calculated for 9 
subsets of markers at different p-value thresholds in the original GWAS 
publications. Best scores for each PRS are presented in (D). R2: 
Nagelkerke’s pseudo-R2; Threshold: P-value threshold in original GWAS. 
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The most significant correlation identified between DLB and each of the 
235 tested traits was with “Years of schooling” (18) reaching a p-value 
of 6.32x10-5 (Bonferroni corrected p-value=0.015) and a correlation 
estimate (rg) of 0.48 (s.e. = 0.12) (Table 1). Interestingly, these scores 
were found to be in the opposite direction in AD, but in the same direction 
in PD (AD: rg=-0.33, p-value=8.87x10-5; PD: rg=0.05, p-value=0.07) 
(Figure 4). A positive correlation was also obtained for “Childhood IQ” 
(19) in DLB and PD, whereas a negative correlation was identified in AD 
(DLB: 0.68, p-value=0.0009; AD: rg=-0.36, p-value=0.0011; PD: 
rg=0.25, p-value=0.0013). Similarly, “Intracranial volume” (20) 
presented a positive correlation with both DLB and PD, but no 
discernible correlation with AD (DLB: 0.69, p-value=0.0052; AD: rg=-
0.003, p-value=0.96; PD: rg=0.34, p-value=0.0005). Conversely, 
“Citrate” (21) was positively correlated with both DLB and AD, but had 
no correlation with PD (DLB: 0.82, p-value=0.0033; AD: rg=-0.21, p-
value=0.25; PD: rg=-0.05, p-value=0.63).  
 
Discussion 
With this study we provide more accurate estimates of genetic heritability 
for DLB, quantify the variance explained by AD and PD polygenic risk 
and estimate pleiotropy between DLB and over 200 diseases and 
biomedical relevant traits. 
Previous heritability estimates for DLB were calculated based on a 
smaller cohort genotyped at a relatively smaller number of sites and using 
GCTA’s GREML-SC (based on a single genetic relationship matrix). 
These earlier studies provided an estimate of 31% heritability for this 
disease (12). It is now recognised that GREML-SC may, under certain 
circumstances (such as causal variants being enriched in regions with 
higher or lower LD than average or if the causal variants had a different 
MAF spectrum than the variants sampled), be biased (16). Because of 
this, we used a recently developed approach that corrects for the LD bias 
in the estimated SNP-based heritability and that is unbiased regardless of 
the properties (e.g. MAF and LD) of the underlying causal variants 
(GCTA GREML-LDMS) (16). We applied this tool to a larger cohort, 
that was imputed with the most recent imputation panel, providing more 
detailed genetic information. Using this approach we estimated that all 
HRC-imputed variants with MAF >0.001 explained 59.9% (s.e= 2.1%) 
of phenotypic variance for DLB, which is nearly double the previous 
estimate (12). Our results also show that a large proportion of the variance 
is explained by variants with lower frequency (MAFs from 0.001 to 
0.01). Given that the current version of HRC allows for imputation of 
variants with frequencies as low as 0.0005 and aggregate R2 above 0.5 
(15), this indicates that performing GWAS in DLB with increased sample 
Fig. 3. Density distribution of polygenic risk scores (PRS) from AD 
and PD in DLB case and control subjects. The curves represent the 
standardized residuals of PRS after adjustment for the first 6 principal 
components. Blue indicates case subjects; orange indicates case 
subjects. 
Fig. 4. Correlation scores with p-value <0.01 in DLB. Shown are also the scores for those same traits in PD and AD. 
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sizes will allow us to identify novel loci involved in conferring risk for 
disease without the need for large-scale whole-genome sequencing. 
One of the explanations for the common issue of “missing heritability” is 
that non-additive heritability (such as dominance variance or epistatic 
variance) represents a substantial component of a trait’s total heritable 
genetic component. Our results suggest that dominance variance has a 
negligible effect on the genetic heritability of DLB, in line with findings 
from 79 unrelated traits (14). However, we cannot exclude that epistatic 
variance plays a role in DLB, given that our cohort is underpowered to 
detect epistatic events. 
Recently, there has been growing interest in the use of PRSs as a way to 
perform risk prediction in various diseases and these have successfully 
been applied to AD (10) and PD (9). To determine how much of the 
phenotypic variance in our DLB cohort can be caused by AD and PD 
known genetic risk factors, we used PRSs from recent GWAS from each 
of these diseases. In both cases scores were predictive of case-control 
status, although explaining only relatively small proportions of variance 
(0.37-1.33%). In AD, excluding the APOE locus greatly reduced the 
amount of variance explained in DLB (0.14%), which is in accordance 
with the strong effect that locus has in the risk of both diseases (4, 22). 
Conversely, excluding the GBA locus in PD had only a modest effect, 
which likely results from the lower frequency in the general population 
of the variants that comprised this signal compared to APOE. Since the 
amount of variance explained by each of the PRS is relatively small, this 
adds to the growing body of evidence that suggests that, genetically, DLB 
is a unique condition and not simply a mix of PD and AD risk factors. 
These data also confirm the polygenic nature of DLB as well as quantify 
the amount of variance that polygenic risk from each of those diseases 
accounts for in DLB. 
Given the large number of pleiotropic events that are being identified for 
a variety of diseases and traits (23, 24), finding correlated conditions 
opens the door to a better understanding of disease pathobiology and 
perhaps may even suggest novel therapeutic targets. Assessing the 
genetic correlation of DLB with over 200 diseases and traits showed 
correlations that were in the same direction of those seen in PD while 
others were in the same direction as in AD. It is interesting to note that 
education scores were positively correlated with DLB, while they have a 
well established negative correlation with AD (25, 26). Similar positive 
correlations have been identified for bipolar disorder and autism 
spectrum disorders (27), as well as for PD in the present data. Also in PD, 
there is evidence for the presence of increased intracranial volumes when 
compared to controls (28). Here, supporting those findings, we identify a 
positive genetic correlation between both PD and DLB with intracranial 
volume, whereas in AD no evidence for genetic correlation was 
identified. Interestingly, the anthropometric characteristics obesity, body 
mass index (BMI) and body fat were negatively correlated with all 3 
diseases. For BMI and PD, recent Mendelian randomization results have 
shown a negative effect (29) which our results replicate and suggest they 
extend to both AD and DLB. A similar finding was obtained for cancer 
traits, where lung cancer showed a general negative correlation with the 
three traits. This agrees with transcriptomic studies that showed that the 
cancer gene expression profile is almost an opposite mirror image to that 
of neurodegenerative disease (30). A positive correlation between both 
DLB and AD with citrate (21) was identified, although this was not the 
case for PD, where no evidence of correlation was found. Increased 
plasma levels of citrate have been shown to be associated with increased 
levels of oxidative stress (31), making it tempting to speculate that in AD 
and DLB oxidative stress may be involved in the neurodegenerative 
processes, while in PD it may be more akin to a consequence. 
Table 1. LDHub correlations with p-value <0.01.  
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We note several limitations in our study. First, the DLB dataset, despite 
being the largest to date, is relatively small when compared to other 
recently published GWAS. This has implications in the statistical power 
to make novel findings and is reflected in the standard errors of the 
analyses performed. We are underpowered to detect rare variants and 
certainly rare variants with small effect sizes. Second, we are unable to 
provide definitive biological mechanisms underlying the genetic 
correlations identified. This means that it is possible that for some of the 
correlations observed, what we are seeing are proxy effects and not direct 
correlations. Lastly, this study focused on individuals of European/North 
American descent. It is likely that studies of populations of different 
ancestries will reveal not only novel loci, but perhaps also novel 
pleiotropic effects, which could improve our understanding of the 
pathobiology of DLB. 
In summary, we provide updated estimates of the genetic heritability of 
DLB and show that dominance variance is not a substantial part of the 
heritability of this disease. We quantify the amount of phenotypic 
variance in DLB that can be attributed to PD and AD polygenic risk 
scores and show that this is relatively small. Lastly, we estimate genetic 
correlations between DLB and over 200 diseases and medically relevant 
traits, shedding light into the complex relationship between DLB and 
both PD and AD. 
 
 
Materials and Methods 
Sample description 
The DLB dataset was previously published (4) and is comprised of 1,216 
cases and 3,791 controls, imputed with HRC v1.1 and includes variants 
with minor allele frequency >= 0.001 and R2>=0.3, for a total number of 
18.4 million variants (median R2=0.92). We used AD summary statistics 
from the International Genomics of Alzheimer's Project (IGAP) (22), 
which is a large two-stage study based upon genome-wide association 
studies (GWAS) on individuals of European ancestry. In stage 1, IGAP 
used genotyped and imputed data on 7,055,881 single nucleotide 
polymorphisms (SNPs) to meta-analyse four previously-published 
GWAS datasets consisting of 17,008 Alzheimer's disease cases and 
37,154 controls (the European Alzheimer's disease Initiative – EADI the 
Alzheimer Disease Genetics Consortium – ADGC, the Cohorts for Heart 
and Aging Research in Genomic Epidemiology consortium – CHARGE, 
the Genetic and Environmental Risk in AD consortium – GERAD). PD 
summary statistics were derived from the International Parkinson’s 
Disease Genomics Consortium (IPDGC) previously published data and 
included 13,708 cases and 95,282 controls (32).  
DLB heritability estimates 
We used the GCTA-LDMS method to estimate heritability based on 
imputed data (16, 33) using an imputation quality above 0.3 and a disease 
prevalence of 0.1%. This method considers the LD-bias that occurs in the 
SNP-based estimates and is unbiased regardless of the properties of the 
underlying variants. We calculated segment-based LD scores using a 
segment length of 200kb (with 100kb overlap between two adjacent 
segments), which were used to stratify the SNPs into quartiles. We then 
estimated the genetic relationship matrix (GRM) for each sample using 
the SNPs in each quartile separately and further stratified by minor allele 
frequency bins (0.001-0.01, 0.01-0.1, 0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5). 
Lastly, we performed restricted maximum likelihood (REML) analysis 
using the multiple GRMs. 
DLB dominance variance estimates 
To estimate the dominance GRM between pairs of individuals, we used 
genome-wide imputed SNPs as implemented in GCTA-GREMLd (14). 
This method calculates the additive and dominance GRMs and fits both 
GRMs in a mixed linear model to estimate additive and dominance 
variance simultaneously. 
PRS analyses 
Determining the polygenic risk of a given phenotype and applying it to 
another trait is an approach that allows to determine shared genetic 
aetiology between traits. We calculated PRSs on the base phenotypes (PD 
and AD), using GWAS summary statistics, and used these as predictors 
of the target phenotype (DLB) in a regression test. To construct and apply 
the PRSs we used PRSice v2.1 (34). We performed clumping on the 
target data by retaining the SNP with the smallest p-value from each LD 
block (excluding SNPs with r2 > 0.1 in 250kb windows). Each allele was 
weighted by its effect-size as estimated in the respective study (for PD 
and AD). Association of PRSs with case-control status was performed 
with logistic regression, and Nagelkerke’s pseudo-R2 was calculated to 
measure the proportion of variance explained. 
Genetic correlation analysis 
To estimate the genetic correlation between DLB and other complex 
traits and diseases, we used a method based on LD score regression and 
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implemented in the online web utility LDHub v1.9.0 (27, 35). The LD 
score regression method uses summary statistics from the DLB GWAS 
and the other available traits, calculates the cross-product of test statistics 
at each SNP, and then regresses the cross-product on the LD score. After 
identifying the most significant correlations for DLB (p<0.01), we 
estimated the correlation of those traits with PD and AD. 
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